Doxercalciferol
| 證據等級: L5 | 預測適應症: 1 個 |
目錄
Doxercalciferol: Original Indication Not on Record → Predicted Vitamin D Deficiency
One-Sentence Summary
Doxercalciferol (DrugBank DB06410) currently has no approved indication or market license on file in this evidence pack, and detailed mechanism-of-action data has not yet been retrieved. The TxGNN model predicts a link to “obsolete vitamin D deficiency” with a very high raw score, but this disease term is itself flagged as obsolete in the underlying ontology, and zero clinical trials, zero ICTRP trials, and zero publications currently support this direction — this is a preliminary, unverified signal, not a validated repurposing hypothesis.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not on record — no approved indications or licenses are documented for this drug in Taiwan |
| Predicted New Indication | Obsolete vitamin D deficiency (disease term flagged as obsolete in source ontology) |
| TxGNN Prediction Score | 99.48% (raw score 0.9948; internal rank 12,348) |
| Evidence Level | L5 — model prediction only, no supporting studies |
| Taiwan Market Status | 未上市 (Not Marketed) |
| Number of Licenses | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data for the drug record itself is not yet available (data gap DG002, DrugBank API lookup pending). However, the model’s own repurposing rationale notes that doxercalciferol is a vitamin D2 prodrug that is hepatically 25-hydroxylated to its active form, which binds and activates the Vitamin D Receptor (VDR).
Based on this mechanistic description, the predicted link to “vitamin D deficiency” overlaps almost completely with the drug’s core, already-known pharmacology — it reads as a restatement of the drug’s own mechanism rather than a novel repurposing hypothesis. In other words, the model may simply be recognizing that a vitamin D analog activates the vitamin D pathway, which is expected and not clinically informative on its own.
Compounding this, the predicted disease node is explicitly marked “obsolete”, suggesting the term may have been deprecated or merged with another concept in the source ontology (e.g., MONDO/UMLS). Combined with the complete absence of clinical trials or literature evidence, the underlying data quality for this specific prediction should be verified before any further evaluation proceeds.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Taiwan Market Information
Doxercalciferol is currently not marketed in Taiwan, with no licenses on record (0 total). No product name, dosage form, or approved-indication data is available to summarize.
Safety Considerations
Please refer to the package insert for safety information.
(Note: key warnings, contraindications, and drug-drug interaction data are not yet available in this evidence pack — TFDA label warnings/contraindications are flagged as a blocking data gap, DG001, required before any safety pre-screening can proceed.)
Conclusion and Next Steps
Decision: Hold
Rationale:
- Evidence level is L5 (model prediction only) with zero supporting clinical trials or literature, and the predicted disease term itself is flagged as obsolete/potentially unreliable in the source ontology.
- The drug is not currently marketed in Taiwan (0 licenses), and a blocking safety data gap (TFDA label warnings/contraindications) prevents progression to the S1 safety pre-screening stage.
To proceed, the following is needed:
- Resolve DG001 (Blocking): retrieve and parse the TFDA package insert for warnings/contraindications.
- Resolve DG002 (High): query DrugBank for confirmed mechanism-of-action data.
- Verify whether “obsolete vitamin D deficiency” maps to a current, valid disease concept before treating this as a genuine repurposing candidate.
- If the disease mapping is confirmed valid, initiate targeted clinical trial and literature searches specific to the corrected disease term.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.